Bioelectrix has been selected as one of twelve companies to present at HealthTech Venture Pulse 2026, bringing together some of Sweden’s most promising healthtech ventures with leading Nordic investors.
More than 60 companies were nominated by leading incubators, accelerators, investor networks and innovation organisations across Sweden. Following a competitive selection process, Bioelectrix was chosen as one of just twelve companies to take the stage.
The selection marks another important step in Bioelectrix’ journey as we continue to advance our bioelectronic technology for hard-to-heal wounds towards clinical use and market.
Over the past year, we have strengthened our technology validation, regulatory and clinical strategy, commercial positioning and international network. Through the CO-AX Accelerator and Sahlgrenska Science Park ecosystem, we have also gained access to valuable expertise, industry connections and investor networks supporting our next phase of growth.
On 9 September in Stockholm, Bioelectrix will meet with investors from across the Nordic healthtech ecosystem to discuss our technology, progress and vision for transforming the treatment of hard-to-heal wounds.
We are grateful to Sahlgrenska Science Park and CO-AX for their continued support, and proud to be selected alongside such a strong group of Nordic healthtech companies.
Read the full story from Sahlgrenska Science Park:
From CO-AX accelerator to investor stage: Brainlink and Bioelectrix selected for HealthTech Venture Pulse 2026